Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world Zhu Chuming (aflibercept biosimilar) in DME and wet AMD
ChiCTR2600116433Phase 4Not yet recruiting
- Sponsor
- Chaoju Eye Care
- Start
- Jan 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of aflibercept in diabetic macular edema (DME) and exudative macular degeneration (2 cohorts), sponsored by Chaoju Eye Care. Primary endpoint: Change in VA from baseline at month 12. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)exudative macular degeneration
Beyond the preview
Go deeper on ChiCTR2600116433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116433.